Phase Ib study of PRT543, an oral protein arginine methyltransferase 5 (PRMT5) inhibitor, in patients with relapsed or refractory, splicing factor-mutant myeloid malignancies Meeting Abstract
| Authors: | Bewersdorf, J. P.; Mi, X.; Lu, B.; Kuykendall, A. T.; Sallman, D.; Patel, M.; Stevens, D. A.; Philipovskiy, A.; Sutamtewagul, G.; Masarova, L.; Keiffer, G.; Uerma, A.; Bhagwat, N.; Heiser, D.; Ro, S.; Hong, W. J.; Abdel-Wahab, O.; Stein, E. M. |
| Abstract Title: | Phase Ib study of PRT543, an oral protein arginine methyltransferase 5 (PRMT5) inhibitor, in patients with relapsed or refractory, splicing factor-mutant myeloid malignancies |
| Meeting Title: | 66th Annual Meeting of the American Society of Hematology (ASH) |
| Journal Title: | Blood |
| Volume: | 144 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2024 Dec 7-10 |
| Meeting Location: | San Deigo, CA |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2024-11-05 |
| Start Page: | 3217 |
| Language: | English |
| ACCESSION: | WOS:001424551300024 |
| DOI: | 10.1182/blood-2024-198495 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
-
364Stein -
584Abdel-Wahab -
17Mi -
6Lu -
102Bewersdorf
Related MSK Work